Sign in
Not yet taking people in Costa RicaNo phase

Following people in Costa Rica with atopic dermatitis who take dupilumab or JAK inhibitors

Follows people with atopic dermatitis treated with dupilumab or JAK inhibitors in Costa Rica.

Key facts

Who runs it
Caja Costarricense de Seguro Social
Where
San José, Costa RicaSee the site
Trial code
Registry title
Atopic Dermatitis Treated With Dupilumab and JAK Inhibitors in Costa Rica
Status
Not yet recruiting
People taking part
50 people, planned
Started
May 2026
Expected to end
May 2031
Type of study
Observational
Treatments tested
  • Abrocitinib
  • Upadacitinib
  • Baricitinib
  • Dupilumab
Record updated
8 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The registry is looking for people in Costa Rica with moderate-to-severe atopic dermatitis who already get systemic or advanced treatment as part of their usual care.

Sex
Everyone can join.
Disease stage
Moderate-to-severe atopic dermatitis that needs systemic or advanced therapy.
Earlier treatment
Must be getting systemic immunosuppressive, biologic, or other advanced treatment as part of routine care.

Main reasons for not taking part

  • Not enough clinical data to assess severity or treatment

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Clinical diagnosis of atopic dermatitis according to accepted diagnostic criteria
  • Moderate-to-severe disease requiring systemic or advanced therapy
  • Receiving systemic immunosuppressive, biologic, or other advanced treatment as part of routine care
  • Evaluated in participating dermatology centers in Costa Rica
  • Available clinical records with baseline and follow-up information

Who cannot take part

  • Lack of sufficient clinical data for severity or treatment assessment

Where in Costa Rica

  • Caja Costarricense del Seguro SocialSan José, Costa RicaContact: Daniel E Barquero-Orias, DermatologistNot yet recruiting

About the trial

What the trial wants to find out

The goal of this observational registry is to characterize the clinical features, severity, treatments, and outcomes of patients with atopic dermatitis in Costa Rica receiving systemic and advanced therapies in routine clinical practice. The main questions it aims to answer are:

Read full original descriptionShow less

What are the demographic and clinical characteristics of patients with moderate-to-severe atopic dermatitis treated in specialized dermatology centers in Costa Rica?

What treatments are used in real-world practice and how do they impact disease severity and patient-reported outcomes over time?

Participants with atopic dermatitis receiving systemic or advanced therapies as part of their usual medical care will be followed longitudinally, with collection of clinical severity scores, treatment patterns, and outcomes during routine visits.

Treatments tested

  • Abrocitinib
  • Upadacitinib
  • Baricitinib
  • Dupilumab

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
National Registry of Patients With Atopic Dermatitis Under Treatment With Dupilumab and JAK Inhibitors Within the Costa Rican Social Security System
Plain-language title
Following people in Costa Rica with atopic dermatitis who take dupilumab or JAK inhibitorsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
8 April 2026